<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04849416</url>
  </required_header>
  <id_info>
    <org_study_id>17746</org_study_id>
    <secondary_id>J2N-MC-JZNJ</secondary_id>
    <nct_id>NCT04849416</nct_id>
  </id_info>
  <brief_title>A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)</brief_title>
  <official_title>A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with&#xD;
      lymphoma or chronic leukemia who have already had standard of care treatment. Participation&#xD;
      could last up to four years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2021</start_date>
  <completion_date type="Anticipated">April 21, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 26, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Randomization through Measured Progressive Disease (Estimated as up to 4 Years)</time_frame>
    <description>ORR as assessed by an Independent Review Committee (IRC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR: Percentage of Participants Who Achieve CR or PR</measure>
    <time_frame>Randomization through Measured Progressive Disease (Estimated as up to 4 Years)</time_frame>
    <description>ORR as assessed by the Investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR): Percentage of Participants with CR, PR, Stable Disease (SD), or Progressive Disease (PD)</measure>
    <time_frame>Randomization to Date of Objective Disease Progression (Estimated as up to 4 Years)</time_frame>
    <description>BOR as assessed by the Investigator and IRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Date of Partial Response (PR) or Better (PR with lymphocytosis or better for CLL/SLL, minor response or better for Waldenstr√∂m macroglobulinemia) to Date of Disease Progression or Death Due to Any Cause (Estimated as up to 4 Years)</time_frame>
    <description>DOR as assessed by the Investigator and IRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Randomization to Objective Progression or Death Due to Any Cause (Estimated as up to 4 Years</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Randomization to Death from Any Cause (Estimated as up to 4 Years)</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7. Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve from Time Zero to last (AUC[0-t) of LOXO-305</measure>
    <time_frame>Cycle 1 Day 1 Predose through Cycle 4 Day 1 Postdose (Cycle = 28 Days)</time_frame>
    <description>PK: AUC(0-t) of LOXO-305</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of LOXO-305</measure>
    <time_frame>Cycle 1 Day 1 Predose through Cycle 4 Day 1 Postdose (Cycle = 28 Days)</time_frame>
    <description>PK: Cmax of LOXO-305</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Disease-Related Symptoms and Health-Related Quality of Life (HRQoL) measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>Baseline through End of Treatment (Estimated as up to 3 Years)</time_frame>
    <description>Five physical function items identified in the EORTC-QLQ-C30 questionnaire (also known as the EORTC IL 19 questionnaire), will be measured. Raw scores for these items range from 0-20, with the highest score indicating worst function</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Leukemia, Lymphoid</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Lymphoma, Mantle-Cell</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Lymphoma, B-Cell, Marginal Zone</condition>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <arm_group>
    <arm_group_label>LOXO-305</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LOXO-305 administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOXO-305</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LOXO-305</arm_group_label>
    <other_name>LY3527727</other_name>
    <other_name>Pirtobrutinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Participants with histologically confirmed B-cell malignancy including:&#xD;
&#xD;
               -  Mantle cell lymphoma (MCL) treated with a prior Bruton's tyrosine kinase (BTK)&#xD;
                  inhibitor containing regimen;&#xD;
&#xD;
               -  CLL/SLL treated with a prior BTK inhibitor containing regimen;&#xD;
&#xD;
               -  Other types of B-cell NHL&#xD;
&#xD;
          -  All participants must have disease requiring treatment, for CLL/SLL participants, at&#xD;
             least 1 indication for treatment consistent with IWCLL 2018 criteria is required&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group 0-2&#xD;
&#xD;
          -  Adequate hematologic status, coagulation, hepatic and renal function&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Lack of adequate wash-out period for investigational agent or anticancer therapy,&#xD;
             major surgery, and radiotherapy prior to the first dose of study treatment&#xD;
&#xD;
          -  Participants requiring therapeutic anticoagulation with warfarin&#xD;
&#xD;
          -  Known central nervous system (CNS) involvement by systemic lymphoma. Primary CNS&#xD;
             lymphoma is excluded&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  Prolongation of the QT interval&#xD;
&#xD;
          -  Test positive for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Current treatment with certain strong cytochrome P450 3A4 (CYP450 3A4) inhibitors or&#xD;
             inducers and/or strong p-glycoprotein (P-gp) inhibitors&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Active second malignancy&#xD;
&#xD;
          -  Prior treatment with LOXO-305&#xD;
&#xD;
          -  Known hypersensitivity to any component or excipient of LOXO-305&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yijishan Hospital, Wannan Medical College</name>
      <address>
        <city>Wuhu</city>
        <state>Anhui</state>
        <zip>241000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>13955309713</phone>
    </contact>
    <investigator>
      <last_name>Dongping Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>010-88196023</phone>
    </contact>
    <investigator>
      <last_name>Yuqin Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>020-87343565</phone>
    </contact>
    <investigator>
      <last_name>Huiqiang Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Medical University Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>020-62786845</phone>
    </contact>
    <investigator>
      <last_name>Ru Feng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hainan Province People's Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>13976595976</phone>
    </contact>
    <investigator>
      <last_name>Li'e Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Hebei University</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <zip>071030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>13930881628</phone>
    </contact>
    <investigator>
      <last_name>Aimin Zang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xingtai People's Hospital</name>
      <address>
        <city>Xingtai</city>
        <state>Hebei</state>
        <zip>054031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>13623292829</phone>
    </contact>
    <investigator>
      <last_name>Zongjiu Jiao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0451 86298104</phone>
    </contact>
    <investigator>
      <last_name>Qingyuan Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science &amp;Technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>13937903068</phone>
    </contact>
    <investigator>
      <last_name>Yan Zhen Guo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13938239725</phone>
    </contact>
    <investigator>
      <last_name>Yanyan Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>15871725926</phone>
    </contact>
    <investigator>
      <last_name>Liling Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>0731-89753999</phone>
    </contact>
    <investigator>
      <last_name>Xielan Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>0731-88651990</phone>
    </contact>
    <investigator>
      <last_name>Hui Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>025-83105910</phone>
    </contact>
    <investigator>
      <last_name>Bing Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0512 67972858</phone>
    </contact>
    <investigator>
      <last_name>Zhengming Jin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0431-88786014</phone>
    </contact>
    <investigator>
      <last_name>Sujun Gao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>021 38804518 25300</phone>
    </contact>
    <investigator>
      <last_name>Guo Ye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Tumor Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0991-7968088</phone>
    </contact>
    <investigator>
      <last_name>Shun'e Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0517-88122261</phone>
    </contact>
    <investigator>
      <last_name>Haiyan Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>028-85420717</phone>
    </contact>
    <investigator>
      <last_name>Ping Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blood Institute of the Chinese Academy of Medical science</name>
      <address>
        <city>Tianjin</city>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>022-23909237</phone>
    </contact>
    <investigator>
      <last_name>Shuhua Yi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>022-23340123</phone>
    </contact>
    <investigator>
      <last_name>Huilai Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 1, 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting</ipd_time_frame>
    <ipd_access_criteria>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

